Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.

被引：0
|
作者：
Li, Regina
Mai, Helen
Chiasson, Kaitlyn
Trudeau, Maureen E.
Chan, Kelvin K.
Cheung, Matthew C.
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Canadian Agcy Drugs & Technol Hlth, Pan Canadian Oncol Drug Review, Toronto, ON, Canada
[3] CADTH, Ottawa, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[5] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14133
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel NitrosoureaA phase II trial of the national cancer institute of canada clinical trials group
    Marc Webster
    Gregory Cairncross
    Stan Gertler
    James Perry
    Nancy Wainman
    Elizabeth Eisenhauer
    Investigational New Drugs, 2005, 23 : 591 - 596
  • [42] Phase II trial of SarCNU in malignant glioma: Unexpected pulmonary toxicity with a novel nitrosourea - A phase II trial of the national cancer institute of canada clinical trials group
    Webster, M
    Cairncross, G
    Gertler, S
    Perry, J
    Wainman, N
    Eisenhauer, E
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 591 - 596
  • [43] PHASE-II STUDY OF ACIVICIN IN NON-SMALL CELL LUNG-CANCER - A NATIONAL CANCER INSTITUTE OF CANADA STUDY
    MAROUN, JA
    MAKSYMIUK, A
    EISENHAUER, E
    STEWART, DJ
    YOUNG, V
    PATER, J
    CANCER TREATMENT REPORTS, 1986, 70 (11): : 1327 - 1328
  • [44] Phase II trial of DPPE and doxorubicin chemotherapy in patients with metastatic breast cancer (MBC): A National Cancer Institute of Canada (NCIC) study
    Khoo, K
    Brandes, L
    Reyno, L
    Dent, S
    Vandenberg, T
    Lebwohl, D
    Fisher, B
    Eisenhauer, E
    ANNALS OF ONCOLOGY, 1998, 9 : 171 - 171
  • [45] The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017
    Chris Skedgel
    Dominika Wranik
    Min Hu
    PharmacoEconomics, 2018, 36 : 467 - 475
  • [46] The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017
    Skedgel, Chris
    Wranik, Dominika
    Hu, Min
    PHARMACOECONOMICS, 2018, 36 (04) : 467 - 475
  • [47] Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada clinical trials group
    Moore, MJ
    Winquist, EW
    Murray, N
    Tannock, IF
    Huan, S
    Bennett, K
    Walsh, W
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2876 - 2881
  • [48] IDENTIFICATION OF NEW DRUGS IN SMALL CELL LUNG-CANCER - PHASE-II AGENTS 1ST
    AISNER, J
    CANCER TREATMENT REPORTS, 1987, 71 (12): : 1131 - 1133
  • [49] Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials
    Rustin, GJS
    Nelstrop, AE
    Bentzen, SM
    Bond, SJ
    McClean, P
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) : 1733 - 1739
  • [50] The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials
    Huynh, My-my
    Pambid, Mary Rose
    Jayanthan, Aarthi
    Dorr, Andrew
    Los, Gerrit
    Dunn, Sandra E.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (11) : 1199 - 1208
12345